5 Best Cheap AI Medicine Stocks to Buy Now

5 Best Cheap AI Medicine Stocks to Buy Now

0 Shares
0
0
0
0
0
0
0

3. RadNet Inc. (NASDAQ:RDNT)

RadNet, Inc. (NASDAQ: RDNT) takes third place because it combines a large operating medical-imaging business with one of the fastest-growing radiology AI platforms in the public market.

The company operates outpatient diagnostic-imaging centers while developing digital-health products through its DeepHealth subsidiary. This structure gives it a significant real-world advantage. AI tools can be developed and tested within an existing imaging network before being offered to outside hospitals, radiology practices and healthcare systems.

The digital-health portfolio uses artificial intelligence to assist with image interpretation, cancer detection, workflow management and clinical reporting. Its technology addresses a major challenge in healthcare: imaging volumes continue to rise while many markets face shortages of trained radiologists.

Reporting Pro, for example, uses AI to help radiologists produce clinical reports and communicate findings more efficiently. Other applications focus on detecting abnormalities in mammography and additional imaging procedures. These products could improve productivity without requiring AI to replace the physician making the final clinical decision.

Second-quarter 2026 total revenue increased 25% to approximately $622.7 million. Digital Health revenue surged 56.5% to $32.4 million, while annual recurring revenue reached $105.5 million—nearly double its level from a year earlier. The company reported record quarterly revenue and raised its financial guidance.

At approximately $73.71 per share and a market capitalization of roughly $5.8 billion, the stock is not cheap based on current GAAP earnings. The company also carries debt and has pursued acquisitions to support growth.

What makes the shares attractive is the combination of an established healthcare operation and rapidly expanding AI revenue. If the digital-health segment maintains its current momentum, it could eventually command a software-style valuation separate from the traditional imaging-center business.

You May Also Like